A strain of Pseudomonas aeruginosa phage HCZ001 and its application

Through Pseudomonas aeruginosa phage HCZ001, the treatment problem of multi-drug-resistant Pseudomonas aeruginosa in pyoderma canine is solved, effective control of canine skin infection is achieved, and good alkali resistance and thermal stability are demonstrated. New treatment options are provided.

CN115322973BActive Publication Date: 2024-11-15EMMEFEI (NANJING) BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202210979371.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-16
Publication Date
2024-11-15
Estimated Expiration
2042-08-16

AI Technical Summary

Technical Problem

Pseudoderma canine caused by Pseudomonas aeruginosa is commonly found in multidrug-resistant bacteria, the existing treatment methods are limited in effect, and there is a lack of effective veterinary application solutions.

Method used

A Pseudomonas aeruginosa phage HCZ001, which has the ability to lyse the multidrug-resistant Pseudomonas aeruginosa, is used to prepare drugs for the treatment of pyoderma canine, including phage compositions and pharmaceutical preparations, with dosage form solutions or coagulation Glue, applied by injection or external use.

Benefits of technology

Pseudomonas aeruginosa phage HCZ001 shows lysis ability across species ranges, good alkali resistance and thermal stability, has significant therapeutic effect on canine skin infection with Pseudomonas aeruginosa, and is preserved and stable for a long time under room temperature.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115322973B_ABST
    Figure CN115322973B_ABST
Patent Text Reader

Abstract

The invention discloses a Pseudomonas aeruginosa phage HCZ001, the Pseudomonas aeruginosa phage (Pseudomonas aeruginosa phage) HCZ001 has a preservation number of CCTCC M 2022666, and the Pseudomonas aeruginosa phage HCZ001 is used in treating canine pyoderma caused by Pseudomonas aeruginosa. The Pseudomonas aeruginosa phage HCZ001 of the invention has the ability of cross-species lysis, good alkali resistance stability, good thermal stability, and can be relatively stably maintained at a high titer level under long-term storage under room temperature conditions, and also has a good therapeutic effect on canine skin infection with Pseudomonas aeruginosa.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of Pseudomonas aeruginosa phages, and in particular to a Pseudomonas aeruginosa phage HCZ001 and an application thereof. Background Art

[0002] Pseudomonas aeruginosa, also known as Pseudomonas aeruginosa, is a Gram-negative conditional pathogen widely distributed in nature. It exists in soil, water, normal human skin, respiratory tract, intestines, etc. When the body's resistance is reduced or the immune system is damaged, it can cause serious infection in human or animal tissues. Pseudomonas aeruginosa has capsules, flagella and pili, no spores, active movement, and is an obligate aerobic bacterium. It survives well on nutrient agar medium, with an optimal growth pH of 5-7, an optimal toxin production temperature of 26°C, and an optimal growth temperature of 36°C. It metabolizes slowly and grows stagnantly at low temperatures of 4°C, but can continue to grow at high temperatures of 42°C. It can produce water-soluble pigments pyocyanin and pyocyanin, which will turn the culture medium bright green. It grows turbidly in liquid culture medium and can form a biofilm on the surface of the culture medium. Pseudomonas aeruginosa can decompose glucose and produce acid, but it does not produce gas and cannot decompose mannitol, maltose, sucrose and lactose. It can decompose urea, is oxidase-positive, and does not form indole. Pseudomonas aeruginosa is a common infectious agent in human nosocomial infections, severe burns, cancer, transplantation, AIDS and other immunocompromising diseases. Pseudomonas aeruginosa infection is also common in companion animals, mainly causing skin, respiratory and urinary tract infections in dogs and cats.

[0003] Bacteriophage (phage) is a general term for viruses that infect microorganisms such as bacteria, fungi, algae, actinomycetes or spirochetes. Because some of them can cause the lysis of host bacteria, they are called phages. Phages use the replication system of the bacterial host to replicate, destroying the host cell (lytic cycle), or reside in the bacterial genome (lysogenic state). In order to initiate their biological infection cycle, phages attach to specific bacterial receptors, so each phage has a specific bacterial host. After attachment, the phage injects its genome into the cell and enlists the bacterial replication machinery to produce phage genomes and proteins, which are assembled inside the host cell. Since phages are much smaller than their host cells, hundreds or thousands of new phages can exist in one bacterial cell. The newly produced phages lyse the host cell and are released into the extracellular environment, where pathogenic bacteria aggregate and are embedded in an extracellular polymer matrix called a biofilm. The formation of a biofilm can make bacteria better resistant to the effects of antibiotics and bactericides. However, bacteriophages can ignore the existence of biofilms and act on pathogenic bacteria. They can penetrate biofilms, replicate inside bacterial cells, and produce enzymes that destroy extracellular polymeric substances, thereby destroying bacteria.

[0004] Since their discovery, bacteriophages have been used to treat patients with bacterial infections, but there are few reports on their clinical application in companion animals. Based on existing practices, phage therapy has a very broad prospect for the treatment of bacterial infectious diseases in companion animals. Although companion animals are not related to the human food chain, they can also serve as hosts for multidrug-resistant bacteria, and their proximity to humans makes them a potential focus for cross-transmission of zoonotic bacteria. Canine pyoderma has a high clinical incidence and is prone to relapse. It has always been a disaster area for the discovery of multidrug-resistant bacteria in veterinary clinics. In response to the above problems, bacteriophages can be used as a powerful tool to combat multidrug-resistant bacteria. The possibility of bacteriophages in the treatment of canine pyoderma is explored, and their effects are evaluated, providing new ideas for the treatment of canine pyoderma. Summary of the invention

[0005] In view of the above technical problems, the present invention provides a bacteriophage capable of lysing multidrug-resistant Pseudomonas aeruginosa, aiming to provide a new treatment plan for canine pyoderma caused by Pseudomonas aeruginosa.

[0006] To achieve the above purpose, the technical solution provided by the present invention is as follows:

[0007] A Pseudomonas aeruginosa phage HCZ001, the Pseudomonas aeruginosa phage (Pseudomonas aeruginosa phage) HCZ001 has a preservation number of CCTCC M 2022666, a preservation date of May 19, 2022, and a preservation address of China Type Culture Collection Center of Wuhan University, Bayi Road, Wuchang District, Wuhan City, Hubei Province.

[0008] As described above, the Pseudomonas aeruginosa phage HCZ001 is used in the preparation of a drug for treating canine pyoderma caused by Pseudomonas aeruginosa.

[0009] A phage composition comprises the Pseudomonas aeruginosa phage HCZ001 as described above.

[0010] A phage pharmaceutical preparation, the active ingredient of which comprises the Pseudomonas aeruginosa phage HCZ001 as described above or the phage composition as described above.

[0011] Wherein, the bacteriophage drug preparation further comprises a pharmaceutically acceptable carrier, the dosage form is a solution or a gel, and the route of administration is injection or external use.

[0012] The Pseudomonas aeruginosa phage HCZ001 has a good disinfecting effect on the host Pseudomonas aeruginosa VHP002 isolated from dogs with pyoderma, and also has a strong disinfecting effect on a strain of Escherichia coli derived from dog feces, and can be used to prepare a drug for treating Pseudomonas aeruginosa infection.

[0013] Compared with the prior art, the present invention has the following beneficial technical effects:

[0014] The Pseudomonas aeruginosa phage HCZ001 of the present invention has the ability of cross-species lysis, good alkali resistance stability, good thermal stability, and can be relatively stably maintained at a high titer level under long-term storage at room temperature, and also has a good therapeutic effect on Pseudomonas aeruginosa infection in dog skin.

[0015] Storage Information

[0016] Pseudomonas aeruginosa phage HCZ001 was deposited in the China Center for Type Culture Collection (CCTCC) on May 19, 2022, with the accession number CCTCC M 2022666. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a plaque picture of Pseudomonas aeruginosa phage HCZ001 of the present invention.

[0018] Figure 2 This is a transmission electron microscope picture of the Pseudomonas aeruginosa phage HCZ001 of the present invention.

[0019] Figure 3 It is the optimal infection multiplicity diagram of Pseudomonas aeruginosa phage HCZ001 of the present invention.

[0020] Figure 4 It is a one-step growth curve diagram of the Pseudomonas aeruginosa phage HCZ001 of the present invention.

[0021] Figure 5 It is a schematic diagram showing the effect of temperature on the activity of the Pseudomonas aeruginosa phage HCZ001 of the present invention.

[0022] Figure 6It is a schematic diagram showing the effect of pH on the activity of the Pseudomonas aeruginosa phage HCZ001 of the present invention.

[0023] Figure 7 It is a schematic diagram of the antibacterial effect of the Pseudomonas aeruginosa phage (Pseudomonas aeruginosa phage) in the HCZ001 culture medium of the present invention.

[0024] Figure 8 This is a schematic diagram of scoring the effect of the Pseudomonas aeruginosa phage HCZ001 of the present invention in controlling Pseudomonas aeruginosa canine skin infection.

[0025] Fig. 9 It is a schematic diagram of the actual effect of the Pseudomonas aeruginosa phage HCZ001 of the present invention in controlling Pseudomonas aeruginosa canine skin infection. DETAILED DESCRIPTION

[0026] The following is a detailed description of the specific embodiments in conjunction with the accompanying drawings, but it should be understood that the scope of the present invention is not limited by the specific embodiments. The raw materials and reagents used in the examples are all commercially available unless otherwise specified. The experimental methods used in the following examples are all conventional methods unless otherwise specified. The quantitative experiments in the following examples were repeated three times, and the results were averaged.

[0027] The host bacteria used in the experiment is a multidrug-resistant clinical strain, which is the Pseudomonas aeruginosa clinical strain VHP002, which was isolated from a skin swab of a dog with pyoderma in an animal hospital in Shenzhen, Guangdong, and was deposited in the China Center for Type Culture Collection together with the Pseudomonas aeruginosa phage HCZ001 of the present invention, with the deposit number of CCTCC M 2022666.

[0028] LB (Luria broth) liquid medium (1 L): peptone 10 g, yeast powder 5 g, NaCl 10 g, add ddH2O to 1 L, adjust pH to 7.0, and sterilize at 121°C for 20 min.

[0029] 0.6% LB semisolid medium (1 L): peptone 10 g, yeast powder 5 g, NaCl 10 g, agar powder 6 g, add ddH2O to 1 L, adjust pH to 7.0, and sterilize at 121°C for 20 min.

[0030] 1.2% LB solid medium (1L): 10g peptone, 5g yeast powder, 10g NaCl, 12g agar powder, add ddH2O to 1L, adjust pH to 7.0, sterilize at 121℃, autoclave for 20min, cool to 50℃, pour into a plate, cool and solidify, then invert for later use.

[0031] SM buffer (1 L): weigh 6.055 g Tris-HCl (pH 7.5) and dilute to 100 ml, add 5.800 g NaCl and 2.000 g MgSO4, and then add ddH2O to dilute to 1 L.

[0032] DNase I, RNase A, PEG8000, phosphotungstic acid (PTA, 2% w / v), and chloroform were commercially available.

[0033] Example 1

[0034] Isolation of Pseudomonas aeruginosa phage HCZ001

[0035] The sample was collected from the sewage of Ruikang Hospital in Nanning, Guangxi. The sample was centrifuged at 4°C and 12000rpm for 10min, and the supernatant was centrifuged repeatedly for 3 times. Finally, the supernatant was filtered with 0.45μm and 0.22μm filter membranes respectively; 5mL of the filtrate was taken, 0.1mL of the host bacteria of the clinical strain VHP002 of Pseudomonas aeruginosa was added, 5mL of 2×LB liquid culture medium was added, and it was placed at 37°C for 14-16h. The next day, the culture obtained after the above culture for 14-16h was centrifuged at 4°C and 12000rpm for 10min, and the supernatant was filtered and sterilized with a 0.22μm filter membrane to obtain the original solution containing the phage, that is, the phage suspension, for later use.

[0036] The host bacteria of the clinical strain VHP002 of Pseudomonas aeruginosa were streaked and inoculated on 1.2% LB solid medium. After culturing overnight, a single clone was picked and inoculated into 5 mL LB (Luria broth) liquid medium. After shaking culture at 37° C. for 8 h, it was used as the host bacteria culture for later use.

[0037] Divide the 1.2% LB solid culture medium into two areas, take 0.1 mL of the above-mentioned standby host bacteria culture and 3 mL of 0.6% LB semi-solid culture medium, mix them evenly, and then spread them on the 1.2% LB solid culture medium. After it is dried, take 10 μL of the above-mentioned standby phage suspension and drop it on one of the areas. After it is naturally dried, place it in a 37°C incubator for culture, and observe whether there are plaques formed in the phage drop area. If plaques are formed, it proves the presence of phages.

[0038] Take another 0.1 ml of the above-mentioned phage suspension and dilute it 10 times. -2 , 10 -4 , 10 -60.1 ml of the diluent was added to 0.1 ml of the host bacteria of the clinical strain VHP002 of Pseudomonas aeruginosa, and the mixture was allowed to stand for 15 min. 3.5 ml of 0.6% LB semi-solid medium at about 45° C. was added, and the mixture was evenly spread on a 1.2% LB solid medium. After culturing at 37° C. for 8 h, the growth of the plaques was observed. A single transparent plaque without a halo, uniform in size, and neatly edged was selected and placed in an EP tube containing 0.1 ml of the spare host bacteria culture and LB liquid culture medium, and co-cultured at 37° C. overnight. The co-culture was centrifuged and filtered on the next day, and the filtrate was diluted 10 times with SM buffer, and double-layered with 0.1 ml of the host bacteria of the clinical strain VHP002 of Pseudomonas aeruginosa. This was repeated about 10 times to obtain phages with uniform plaque size, which were stored at 4° C. for later use.

[0039] The above-mentioned spare phage was tested by double-layer plate method (i.e. double-layer agar plate method), and the results were as follows Figure 1 As shown, the phage can form needle-shaped translucent plaques in agar culture medium, with no halo around and clear and regular edges, which is a typical lytic phage.

[0040] Example 2

[0041] Amplification and Purification of Pseudomonas aeruginosa Phage HCZ001

[0042] Take 0.1 ml of the phage stored at 4°C in Example 1 and 0.1 ml of the host bacteria culture stored in Example 1 in a test tube for 15 min, add 10 ml of LB liquid culture medium, culture at 37°C for 6 h, centrifuge at 4°C and 12000 rpm for 20 min, take the supernatant, filter with a 0.22 μm filter membrane, and the filtrate is the phage lysate.

[0043] PEG purification: DNase I and RNase A were added to the phage lysate to a final concentration of 1 μg / ml, incubated at 37°C for 30 min, added with NaCl to a final concentration of 1 M and placed on ice for 1 h (i.e., sodium chloride was added to make the final concentration of sodium chloride in the mixed solution 1 M), centrifuged at 4°C and 12000 rpm for 10 min, the supernatant was added with PEG8000 to a final concentration of 10%, incubated at 4°C overnight, then centrifuged at 4°C and 12000 rpm for 10 min, the supernatant was discarded, inverted for 5 min, excess water was removed as much as possible, and then SM buffer was added to the remaining solid matter to resuspend, an equal volume of chloroform was added and gently shaken for 30 s, centrifuged at 4°C and 5000 rpm for 15 min to separate the organic phase and the hydrophilic phase, and the hydrophilic phase containing the phage particles was recovered to obtain a purified phage suspension.

[0044] The double-layer plate method was used to detect the phage titer: the purified phage suspension was diluted 10 times in a gradient, 0.1 ml of each gradient of phage dilution was taken and mixed with 0.1 ml of the host bacterial solution of the clinical strain of Pseudomonas aeruginosa VHP002, and then spread on a double-layer agar plate. The plate was cultured at 37°C for about 6-10 hours, and the plaques were counted on each agar plate. The plate with about 30-300 plaques was selected. The initial phage concentration calculated according to the dilution multiple was the phage titer. The phage titer (PFU / ml) = dilution multiple × number of plaques × 10, and the phage titer was 3 × 10 9 PFU / ml.

[0045] Example 3

[0046] Observation of Pseudomonas aeruginosa phage HCZ001 by transmission electron microscopy

[0047] The purified phage suspension of Example 2 was observed under an electron microscope. The purified phage suspension of Example 2 was dropped on a copper sheet and allowed to precipitate naturally for 5 to 10 minutes. Excess liquid was removed with filter paper and stained with a drop of 2% phosphotungstic acid (PTA, 2% w / v). After drying at room temperature, the suspension was observed under a transmission electron microscope. The results are shown in FIG. Figure 2 (100kV) shows that the phage has a regular icosahedral head with a diameter of about 150nm and a tail of 100nm. According to the "Virus Classification-The Eighth Report of the International Committee on Taxonomy of Viruses" published by the International Committee on Taxonomy of Viruses (ICTV) in 2015, the phage belongs to the Myoviridae family and is named HCZ001.

[0048] Example 4

[0049] Determination of the optimal multiplicity of infection of Pseudomonas aeruginosa phage HCZ001 (the multiplicity of infection is the ratio of the number of phages to the number of host bacteria at the initial stage of infection)

[0050] Take the host bacterial culture prepared in Example 1 and adjust the concentration to 1×10 9 CFU / mL, the phage prepared in Example 1 and the host bacteria culture prepared in Example 1 were added at a ratio of 1000, 100, 10, 1, 0.1, 0.01, and 0.001, respectively, and LB liquid culture medium was added to make the total volume of the culture system the same, and static culture was carried out at 37°C for 6h, and centrifuged at 10000rpm for 10min, and the supernatant was collected and diluted to an appropriate concentration, and the titer was determined by the double-layer method. The results are as follows Figure 3 As shown, the optimal infection multiplicity of Pseudomonas aeruginosa phage HCZ001 is 1.

[0051] Example 5

[0052] Determination of one-step growth curve of Pseudomonas aeruginosa phage HCZ001

[0053] The host bacterial culture prepared in Example 1 was mixed with an excess of the phage prepared in Example 1 (MOI>10, to ensure that all bacteria and phages are adsorbed), incubated at 37°C for 15 minutes, centrifuged at 12000rpm for 1 minute, and the supernatant (unadsorbed phage) was discarded. The precipitate (mutually adsorbed bacteria and phage particles) was washed once with LB liquid culture medium, and the precipitate was resuspended with 10ml of preheated LB liquid culture medium, and quickly placed in a 37°C shaker for shaking culture. Starting from 0min, 120μl of the culture was taken every 10min, and the bacteria were removed by centrifugation at 4°C and 10000rpm for 2min. The supernatant was taken and diluted to an appropriate concentration (an appropriate concentration is a concentration that forms 30-300 plaques on the plate), and the phage titer was determined by the double-layer plate method. The measurement lasted for 120min, and a total of 13 samples were taken. The sampling time was used as the horizontal axis, and the logarithm of the phage titer was used as the vertical axis. A one-step growth curve was drawn to obtain the incubation period, outbreak period, and outbreak volume of the phage. The results of the one-step growth curve are shown in FIG. Figure 4 As shown, the incubation period of infection of the host bacteria is 10 minutes, the outbreak period is 40 minutes, and the outbreak volume is 52 PFU / cell.

[0054] Example 6

[0055] Temperature and pH tolerance experiment of Pseudomonas aeruginosa phage HCZ001

[0056] Take 10 sterile EP tubes, add 0.5 ml of the reserved phage in Example 1 to each tube, and act at 30°C, 40°C, 50°C, 60°C, 70°C, and 80°C for 60 min, take out 100 μl every 10 minutes and immediately cool it in a water bath, and then measure the phage titer; the test results are as follows: Figure 5 As shown: the phage can withstand high temperatures of 50°C, and the titer is basically stable within 50 minutes. When the temperature is greater than 60°C, the phage titer decreases significantly over time. In a 60°C environment, the titer is basically stable within 10 minutes, and then begins to decrease to inactivation. The phage is rapidly inactivated in 70°C and 80°C environments.

[0057] Eleven portions of 0.1 ml of the phage prepared in Example 1 were placed in SM buffer (0.9 ml) at pH 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 13, respectively, and reacted at 37° C. for 1-2 h. The titer of the phage after the reaction was then determined by the double-layer plate method. The test results are shown in FIG. Figure 6As shown: the titer of Pseudomonas aeruginosa phage HCZ001 changes little in an environment with a pH value of 6-8, and the activity remains basically unchanged; when the environmental pH is > 8 or pH < 6, the titer of the phage decreases with the increase of acidity and alkalinity; when pH > 13 or pH < 3, the phage titer is 0 and is completely inactivated. Therefore, it can be seen that the optimal pH for the phage is 6-8.

[0058] Example 8

[0059] Antibacterial effect of Pseudomonas aeruginosa phage HCZ001 in culture medium

[0060] The experiment was divided into 5 test groups, with concentrations of 1×10 6 , 1×10 7 , 1×10 8 Phage group (phage used in Example 1), positive control group, negative control group. Each group was subjected to 3 repeated experiments. 100 μL phage solution and 100 μL LB broth of different concentrations were added to each well in the phage group, and 200 μL LB broth was added to both the positive control group and the negative control group. In addition to the negative control group, 5 μL of Pseudomonas aeruginosa clinical strain VHP002 bacterial solution was inoculated into all test wells. After the addition of samples, the initial OD450 value was tested on the microplate reader, and the 96-well plate was placed in a 37°C incubator for incubation for 16 hours. The changes in the OD450 value were taken out every hour for testing, and each test was repeated 3 times. After that, a curve graph was drawn. The results are shown in the figure. Figure 7 As shown, it can be seen that the higher the phage concentration, the better the antibacterial effect.

[0061] Example 9

[0062] Experiment on the Control of Pseudomonas aeruginosa Skin Infection in Dogs by Pseudomonas aeruginosa Phage HCZ001

[0063] The experiment was conducted in the animal room of Guangxi University. The experimental subjects were two experimental dogs, both of which were mixed-breed beagles about 1 year old, weighing about 5 kg. Both were female dogs, neither of which was sterilized and had complete immunization and deworming. The experimental dogs were divided into two groups, one in each group, namely the phage treatment group and the positive control group. All drugs in the experiment were administered by subcutaneous injection.

[0064] First, Pseudomonas aeruginosa was used to create a model of pyoderma. Three pieces of skin with an area of ​​5×5 cm were selected for each dog, and the hair was shaved. The skin was scrubbed and disinfected with alcohol and chlorhexidine. Then a microneedle roller was used to dip into the bacterial solution and inoculate the bacteria on the skin. The inoculation was done once every 24 hours for a total of 5 days. The dog was then observed for 72 hours. Treatment could be started if there was no sign of improvement in the skin.

[0065] Take the spare phage of Example 1 and adjust the phage concentration to 10 9PFU / mL, 1 mL was given to each modeling site once a day; from the beginning of modeling, the experimental site was scored every 24 hours according to the itch scoring scale (Table 1), cytological bacterial count scale (Table 2) and apparent skin lesion scale (Table 3).

[0066] Table 1 Itch Rating Scale

[0067]

[0068]

[0069] Table 2 Cytological bacteria count table

[0070]

[0071] Table 3 Table of apparent skin pathology variables

[0072]

[0073] After the experiment, the scores of the three tables were combined and a curve graph was drawn. The results are as follows Figure 8 shown.

[0074] After successful modeling and treatment, photos of the modeled skin area were taken. Fig. 9 As shown, it can be seen that the skin treated with phages showed a significant improvement in visual appearance within a short period of time, while the skin not treated with phages showed almost no signs of improvement.

[0075] The foregoing description of specific exemplary embodiments of the present invention is for the purpose of illustration and demonstration. These descriptions are not intended to limit the present invention to the precise form disclosed, and it is clear that many changes and variations can be made based on the above teachings. The purpose of selecting and describing the exemplary embodiments is to explain the specific principles of the present invention and its practical application, so that those skilled in the art can realize and utilize various different exemplary embodiments of the present invention and various different selections and changes. The scope of the present invention is intended to be limited by the claims and their equivalents.

Claims

1. A Pseudomonas aeruginosa phage ( Pseudomonas aeruginosa phage) HCZ001, characterized in that The Pseudomonas aeruginosa phage ( Pseudomonas aeruginosa phage) HCZ001 accession number is CCTCC M2022666.

2. Use of the Pseudomonas aeruginosa phage HCZ001 as claimed in claim 1 in the preparation of a drug for treating canine pyoderma caused by the host bacteria of the clinical strain VHP002 of Pseudomonas aeruginosa.

3. A bacteriophage composition, characterized in that: It comprises the Pseudomonas aeruginosa phage HCZ001 as claimed in claim 1.

4. A bacteriophage pharmaceutical preparation, characterized in that: The active ingredient of the phage pharmaceutical preparation comprises the Pseudomonas aeruginosa phage HCZ001 as claimed in claim 1.

5. A bacteriophage pharmaceutical preparation, characterized in that: The active ingredient of the phage pharmaceutical preparation comprises the phage composition according to claim 3.

6. The bacteriophage pharmaceutical preparation according to claim 4 or 5, characterized in that: The bacteriophage drug preparation further comprises a pharmaceutically acceptable carrier, the dosage form is a solution or a gel, and the administration route is injection or external use.

Citation Information

Patent Citations

  • Pseudomonas aeruginosa bacteriophage and application thereof in prevention of hemorrhagic pneumonia of mink

    CN103981154A

  • Pseudomonas aeruginosa phage and application thereof

    CN110144333A

  • High-cracking pseudomonas aeruginosa bacteriophage RDP-PA-20001 and application thereof

    CN112522214A